Alcon announced that its Voyager direct selective laser trabeculoplasty (DSLT) device is now commercially available in the United States. The Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser is the first and only contactless laser for glaucoma, the company said in a press release.
Voyager DSLT is fully automated, efficiently delivering 120 laser pulses without the need for a gonio lens as with manual SLT. Image courtesy Alcon.
Voyager DSLT is controlled through a touchscreen, taking the slit lamp and manual gonio lens aiming out of the equation, and reduces the specialized training required with manual select laser trabeculoplasty (SLT), the company reported.
The GLAUrius trial found that DSLT delivers effective intraocular pressure (IOP) control and has a strong safety profile with low risk of adverse events, with 62% of DSLT participants medication-free at 12 months.
The DSLT device, originally developed by Israeli company Belkin Vision, received 510(k) clearance from the US Food and Drug Administration (FDA) in late 2023. Alcon acquired Belkin Vision during the summer of 2024. The Voyager DSLT is also available in certain markets in the European Union and United Kingdom.